TITLE

They're Dying to Get In

AUTHOR(S)
Bjerklie, David
PUB. DATE
April 2002
SOURCE
Time;4/22/2002, Vol. 159 Issue 16, p56
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discusses the difficulty of being able to participate in clinical trials in medicine. Benefits of the trials, including substantial doctor-patient interaction; Idea that it is not just the terminally ill who benefit from the attention, but also medically neglected or poorly informed subjects who may learn of previously undiagnosed conditions; Issue of access to drugs after trials are finished.
ACCESSION #
6520017

 

Related Articles

  • Improving Topical Microbicide Applicators for Use in Resource-Poor Settings. Vail, Janet G.; Cohen, Jessica A.; Kelly, Kimberly L. // American Journal of Public Health;Jul2004, Vol. 94 Issue 7, p1089 

    With more than 60 potential microbicides being assessed in preclinical or clinical trials, most attention has been centered on products intended for topical application, with much less research conducted on the applicators that will be used to deliver the microbicides. However, applicator design...

  • Funding a Clinical Trial: The Perspective of a Medicines Funder. Alsop, Peter; Metcalfe, Scott; Evans, Jackie // PharmacoEconomics;2008, Vol. 26 Issue 10, p811 

    The article discusses the role of funding agencies in clinical trials. Well documented examples of industry-funded research not addressing important public good questions are presented. It is said that public funders of medicines actively seek information in addition to that provided by funding...

  • Should healthy volunteers in clinical trials be paid according to risk? Jones, Eleri; Liddell, Kathleen; Saunders, John // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/16/2010, Vol. 340 Issue 7738, p130 

    The authors claim that healthy volunteers in clinical trials should be paid according to risk. They pointed out that the action of volunteers is a gift to the society due to the higher risks in some clinical trials. They also think that this kind of voluntarism is inconsistent with other...

  • Sex and Race in Clinical Trials. Wechsler, Jill // Applied Clinical Trials;Aug2004, Vol. 13 Issue 8, p19 

    Comments on the importance of standards and research methods aimed at providing more useful information on population subgroups. Struggles of the research community to obtain information about variable drug effects on patients based on race, ethnicity, gender and age; Campaign to move away from...

  • Halt to microbicide trial sets back AIDS research. Moszynski, Peter // BMJ: British Medical Journal (International Edition);2/10/2007, Vol. 334 Issue 7588, p276 

    The author reports that two phase III clinical trials of a topical microbicide gel, cellulose sulfate, in testing for prevention of HIV in women have been stopped due to preliminary results that demonstrated an increased risk of HIV infection. Separate phase III trials of three other...

  • CHAPTER 26: Design Principles and Their Application in Preventive Field Trials. Brown, C. Hendricks // Handbook of Drug Abuse Prevention: Theory, Science, & Practice;2003, p523 

    The article provides a framework for assessing the quality of a preventive field trial. Such a framework is useful for three purposes. First, research scientists can direct their attention to a limited number of essential elements in designing and implementing new preventive trials. Second,...

  • How to Find a Trial. Smith, Ian K. // Time International (South Pacific Edition);11/22/99, Issue 47, p76 

    Offers information on patient enrollment in clinical drug trials. Researchers' need for patients as well as patients' need for treatment; Reasons adults do not participate in clinical drug trials; Where to locate trials. INSETS: Ace-ing It;Inside Information;Minitel Mini-Stroke;Couch Potatoes...

  • Blinding in clinical trials and other studies. Day, Simon J; Altman, Douglas G // BMJ: British Medical Journal (International Edition);08/19/2000, Vol. 321 Issue 7259, p504 

    Discusses the relevance of allocation concealment, or blinding, in clinical trial practice. Importance of blinding in trials when response criteria is subjective; Difficulties involved in conducting double blind trials; Risk of bias associated with inadequate blinding; Use of blinding in other...

  • Clinical Trial watch.  // Urology Times;1/1/2006, Vol. 34 Issue 1, p25 

    The article presents a list of clinical trials related to urology that were conducted in the U.S. In one of the trials Paciltaxel, Carboplatin and Gemcltabine are used for the Treatment of patients with Advanced Transitional Cell Cancer of the Bladder. In another trial researchers are studying...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics